|
|
Weight-Management Outlook 2010Published by: PharmaLive Special Reports Published: Feb. 1, 2010 - 93 Pages Table of Contents
AbstractBy 2015, the World Health Organization projects that there will be 2.3 billion overweight adults and 700 million obese adults around the world. The U.S. has the highest obesity rates worldwide. Rates of obesity in developing countries have tripled during the past two decades. Despite these glaring statistics, the global obesity market was valued at only $2 billion during 2008 due to a limited availability of therapeutic options.During the past two decades, prescription treatments for the obesity category have come under increased scrutiny by FDA, physicians, and patients. Radical heart-related side effects led to the market withdrawal of Fen-Phen in the 1990s. During 2009, safety concerns increased with FDA's response to reports of liver injury in patients taking GlaxoSmithKline's alli and Roche's Xenical, both containing the active ingredient orlistat. And in January, FDA notified physicians that Abbott Laboratories' Meridia may lead to an increased risk of heart attack and stroke in patients with a history of cardiovascular disease. In addition to safety concerns, companies have hesitated to develop weight-control drugs because of insufficient scientific knowledge and refusal of healthcare regulators to grant reimbursement for such products. Although the pharmaceutical industry has lead discovery for weight-management products in the past, biotechnology and biopharmaceutical companies are emerging as the new leaders in developing and bringing obesity products to market. These products are expected to be effective and safe, and are anticipated to assist with related conditions such as diabetes and blood pressure. Promising late-stage pipeline products include Arena Pharmaceuticals' lorcaserin, Vivus' Qnexa, and Orexigen Therapeutics' Contrave. IntraPace Inc.'s abiliti system is an investigational device designed to provide stimulation to the stomach when food or drink is detected to create an early feeling of fullness. Abiliti contains sensors intended to track consumption and physical activity data, which can be downloaded at a doctor's office and used to monitor a patient's progress toward weight-loss goals. Meanwhile, other companies are developing scientifically advanced electroencephalograph (EEG) equipment to help with obesity and related conditions. These brain-monitoring systems are considered lower-cost and space-saving alternatives to traditional MRI and CT equipment. In this report, readers can get insight into the product pipelines for weight management and obesity as well as the therapeutic areas related to these conditions, including diabetes, heart disease, and hypertension; review qualitative analysis of the most promising weight-control drugs and emerging discovery and development strategies; track potentially competitive products, identify those that have market-leading potential, and learn how these could affect your company's market share; understand the competitive landscape and future growth drivers shaping the weight-control market; uncover partnership opportunities within the weight-control market that could improve your company's product portfolio; learn how treatment of overweight and obesity will impact development in related therapeutic areas. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||